Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management

Cited by (508)

Items 201–300 of 508

1. Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relapse
   Qi Chen, Tian Tian, Y. Eric Shi, Xuxing Shen, H R Qiu, Yuanyuan Jin, Lijuan Chen, R H Guo · 2026 · The Oncologist
2. Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma
   Seungbin Han, Larissa Haertle, Umair Munawar, Marietta S. Truger, Ann-Sophie Hainold, Chien‐Yun Lee, Shilpa Kurian, Christina Verbruggen, Silvia Nerreter, Cornelia Vogt et al. · 2026 · Clinical Epigenetics
3. How Laboratory Innovations Are Shaping the Future of Multiple Myeloma Care
   Joana Caetano, Ana Marta Pires, Carlos M. A. Costa, Rui Bergantim, Adriana Isabel Roque, Patrícia Ferraz, Maria Rosário Cunha, Niccolò Bolli, Noemí Puig, Cristina M. Joao · 2026 · Cancers
4. Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data
   Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar · 2026 · British Journal of Haematology
5. Extracellular Enolase-1 Promotes CAF-Associated Stromal Reprogramming via the Plasmin/TGF-β Axis in Multiple Myeloma
   I‐Che Chung, Tung‐Yueh Chuang, Yu-Tung Ko, Mao-Lin Chen, Po-Yang Hsu, Wei-Ching Huang, Ta-Tung Yuan · 2026 · Cancers
6. Circadian Deregulation in Multiple Myeloma: BMAL1 / CLOCK Expression Patterns and Diagnostic Performance
   Hamide Albayrak, Mustafa Ertan Ay, Anıl Tombak · 2026 · International Journal of Laboratory Hematology
7. NGS-based MRD monitoring in mature B-cell and plasma cell malignancies
   Roisin M. McAvera, Siobhan V. Glavey · 2026 · Academia molecular biology and genomics.
8. Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression
   Ainsley Ryan Yan Bin Lee, Hon Jen Wong, Chi Ching Lim, Sanjay De Mel, Melissa Gaik Ming Ooi, Wee Joo Chng, Yu Yang Soon, Cinnie Yentia Soekojo · 2026 · Transplantation and Cellular Therapy
9. NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma
   Bo Hu, Jacob T. Edwards, Hardik Modi, Jim Gamez, Oscar Enrique Echeagaray, Kyle N. Hess, Yue Ren, Diana Anderson, Marta Larráyoz, Jin‐Yi Zhu et al. · 2026 · Blood
10. Circulating M‐ MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study
    Qi Yan, Bin Chu, Mengru Liu et al. · 2026 · Clinical and Translational Science
11. Non-cryopreserved hematopoietic stem cell transplantation compared to conventional autologous peripheral stem cell transplantation with cryopreserved stem cells among patients newly diagnosed with myeloma
    Ece Vural, Ramazan Öcal, Hamit Aytekin, İlknur Aksoyoğlu, Oral Nevruz, Osman İlhan, Meral Beksac · 2026 · Transfusion and Apheresis Science
12. Lenalidomide-Associated Oral Pigmentation: A Case Report
    André Luís Santana de Freitas, Fabiana Gomes Cardoso Pereira de Sousa, Cléverson Teixeira Soares · 2026 · Head and Neck Pathology
13. Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database
    Maria Jacqueline Nieto, Yu-Hsuan Shih, Jiaqi Fang · 2026 · Leukemia & lymphoma/Leukemia and lymphoma
14. Multimodal melphalan delivery: improved safety and outcomes with autologous myeloma transplant in India
    A. Joy, A. Philip, R. Muralikrishnan, K. Niraimathi, R. Zachariah, P. Thekkur, A. Doshi, M.P. Arya, K. Ajith, V. Hari et al. · 2026 · Public Health Action
15. Myeloma and MGUS
    Matthew J. Streetly · 2025 · Medicine
16. Anti-CD38 Antibodies in Monotherapy for Patients with Relapsed/Refractory Multiple Myeloma: Real-World Clinical Practice and Results of Clinical Trials
    Маргарита Андреевна Ульянова, Vladimir I. Vorobyev, Liudmila A. Bychenkova · 2025 · Clinical oncohematology
17. Non-secretory Multiple Myeloma: A Report of a Rare Case
    Jacob T Harris, Alexa F. Viniotis, John Bibb · 2025 · Cureus
18. Minimising Toxicity and Maximising Response: T-Cell Engagers for Elderly Patients with Multiple Myeloma
    Anthony McLoughlin, Matthew J. Rees · 2025 · Lymphatics
19. Dexamethasone desensitization in type III hypersensitivity reaction and multiple myeloma
    Rosalaura Virginia Villarreal-González, Leslie Astrid de la Fuente, Diana Laura García-Soto · 2025 · Journal of Oncology Pharmacy Practice
20. Long non-coding RNA FEZF1-AS1 suppresses ferroptosis in multiple myeloma cells through KIAA1429-mediated m6A modification
    Qing Su, Weiliang Liu, Peijin Wang · 2025 · Human Cell
21. Single-cell transcriptomics identifies PDIA4 as a marker of progression and therapeutic vulnerability in multiple myeloma
    Wenjie Yu, Jiamin Zhan, Yanxia Wang et al. · 2025 · Journal of Translational Medicine
22. Highly multiplexed imaging recovers immune and metabolic niches in multiple myeloma associated with disease progression and bone involvement
    Ingrid Aass Roseth, Lukas Hatscher, C. Schiller, Håkon Skjalg Selland Johnstuen, Tobias Schmidt Slørdahl, Håkon Hov, Denis Schapiro, Therese Standal · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
23. Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple Myeloma
    Dor David Abelman, Jenna Eagles, Aimee Wong, Saumil Shah, Jeffrey P. Bruce, Stephanie Pedersen, David S. Scott, Cecília Bonolo de Campos, Signy Chow, Ellen nong Wei et al. · 2025 · medRxiv
24. Flower-Shaped Plasma Cells in Multiple Myeloma with Morphological Heterogeneity
    Hiroki Hosoi, Misato Tane, Makiko Sogabe · 2024 · Diagnostics
25. CD34+ and CD34− MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34+ MM cells
    Ayano Fukui-Morimoto, Kentaro Serizawa, Ko Fujimoto, Aki Hanamoto, Yoshio Iwata, Hiroaki Kakutani, Takahiro Kumode, Chikara Hirase, Yasuyoshi Morita, Yoichi Tatsumi et al. · 2024 · International Journal of Hematology
26. [Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)].
    Yan Li, J R Liu, Jian Li · 2024 · PubMed
27. Cell indices as predictors of progression-free survival in multiple myeloma: a retrospective cohort study
    Viet Trung Han, Minh Phuong Vu, Phuong Thao Pham · 2025 · ONCOLOGIE
28. Myélome multiple : ce que le rhumatologue doit savoir en 2025
    Rakiba Belkhir · 2025 · Revue du Rhumatisme
29. PHLPP and LAMP2 predict favorable treatment response and survival in multiple myeloma patients who receive induction treatment with bortezomib
    Qingkun Han, Wei Han, Cuiping Li · 2025 · Irish Journal of Medical Science (1971 -)
30. Immunophenotypic characteristics and prognostic value of peripheral blood circulating plasma cells in patients with newly diagnosed multiple myeloma
    Hong Chen, Yuan Zhao, Zhiyu Zhang · 2025 · Journal of Medical Biochemistry
31. Assessment of prognostic risk of death in patients with multiple myeloma based on CD184 and CD269: A retrospective analysis
    Hong Chen, Yuan Zhao, Zhiyu Zhang · 2025 · Journal of Medical Biochemistry
32. Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial
    Ya‐Lan Zhou, Jinqiao Zhang, Wei Wang, Li Bao, Bai‐Jun Fang, Da Gao, Liping Su, Wenming Chen, Guangzhong Yang · 2025 · Cancer Medicine
33. Advances in the Pathophysiology, Diagnosis, and Treatment of Lymphomas: A Comprehensive Overview
    Maaweya Jabareen, Muhammad Al-Sweity, Wasef Alhroub · 2025 · IntechOpen eBooks
34. Plasmacytoma of the distal tibia: A case report
    Long Ma, Zhifeng Gu, Zongqiang Yang · 2025 · Asian Journal of Surgery
35. Emergency Medicine Clinics Hypercalcemia/Multiple Myeloma
    Andrew Kalnow, Rodney Fullmer · 2025 · Emergency Medicine Clinics of North America
36. Unusual Presentation of Multiple Myeloma with Cranial Nerve Palsy: A Case Report and Review of Literature
    Bijita Dutta, Ankita Mukhopadhyay, Sonia Gon · 2025 · The Journal of Medical Sciences
37. Functional Role of Granulocytic Myeloid-Derived Suppressor Cells in CAR-T Therapy: Insights from Single- Cell RNA Sequencing in Multiple Myeloma
    Chao Zhang · 2025 · Research Square
38. Diagnostic Methods Used in Detecting Multiple Myeloma in Paleopathological Research—A Narrative Review
    Kinga Brawańska, Cyprian Olchowy, Grzegorz Mikita · 2025 · Heritage
39. Is Consolidation Therapy Effective in Multiple Myeloma Patients after High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Single Center Real-Life Data with Cyclophosphamide-Bortezomib-Dexamethasone or Bortezomib-Lenalidomide-Dexamethasone?
    Şeyma Yıldız, Asil Demirezen, Zeynep Arzu Yeğin, Münci Yağcı, Zübeyde Nur Özkurt · 2025 · Indian Journal of Hematology and Blood Transfusion
40. Periportal Collar Sign: A Potential Sonographic Pattern of Multiple Myeloma
    Renato Farina, Francesco Lionetti, Pietro Valerio Foti · 2025 · Journal of diagnostic medical sonography
41. Analysis of clinical characteristics, treatment response, and prognosis among 67 patients with anaplastic multiple myeloma
    Fei Chen, Yan Wang, Zhongxia Huang, Man Qi, Hong Chen · 2025 · World Journal of Surgical Oncology
42. Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma
    Liying Peng, T. Shan, Xinyi Zhou, Zhong-Yuan Feng, Wan-Ting Qiang, Jing Lu, Hai-Yan He, Juan Du · 2025 · OncoTargets and Therapy
43. Hydroxylation near the epoxyketone of carfilzomib confers protection from microsomal epoxide hydrolase-mediated metabolism
    Seongsoo Lee, Jun Young Jang, Chan Bae · 2025 · Drug Metabolism and Disposition
44. Combining PIM‐2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding
    Zhaoyun Liu, Wenhui Lei, Xiaohan Liu · 2025 · Advanced Science
45. Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma
    Vincenzo Sammartano, Sara Ciofini, Beatrice Esposito Vangone · 2025 · Mediterranean Journal of Hematology and Infectious Diseases
46. CALR regulates the proliferation and drug sensitivity of multiple myeloma cells through the BCL2 signaling pathway
    Yin Wang, Xiaoli Hu, Yaqi Song · 2025 · Molecular Biology Reports
47. Which Calculations Are Required for Treating Patients with Multiple Myeloma?
    Александр Сергеевич Лучинин, Anna Semenova · 2025 · Clinical oncohematology
48. Management of Relapsed/Refractory Myeloma in Resource Constrained Setting
    L. Rohit Reddy, Lalit Kumar, Prabhat Singh Malik · 2025 · Clinical Lymphoma Myeloma & Leukemia
49. Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma
    Hongmei Zhou, Min Zhang, Yi Jin, Xianghua Lang · 2025 · Hematology
50. Unexpected progression of lymphoplasmacytic lymphoma with TP53 deletion after treatment for concurrent multiple myeloma with IGH:: CCND1
    Aika Kitamura, Kohei Shiroshita, Shinya Fujita et al. · 2025 · Leukemia & lymphoma/Leukemia and lymphoma
51. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant
    Curtis Marcoux, Denái R. Milton, Mark R. Tanner et al. · 2025 · Transplantation and Cellular Therapy
52. Immunopathological syndromes associated with adaptive immunity
    Kozlov Va, Andrei A. Savchenko, Andrei S. Simbirtsev · 2025 · Cytokines and inflammation
53. Influencing factors associated with symptom profiles among multiple myeloma patients: A latent profile analysis
    Ting Wang, Yingying Lin, Leiwen Tang, Junxiang Sun, Weiwei Chen, Yanke Mao, Yao Ge, Huan Liu · 2025 · Research Square
54. Paraproteins: A Potential Source of Fallacy in Bilirubin Assay
    Garima Chauhan, Bijita Dutta, Arpita Chandra · 2025 · The Journal of Medical Sciences
55. B Cell-Derived and Non-B Cell-Derived Free Light Chains: From Generation to Biological and Pathophysiological Roles
    Linyang Li, Huining Gu, Xiaoyan Qiu · 2025 · International Journal of Molecular Sciences
56. Genetic evidence reveals phosphatidylcholine as a mediator in the causal relationship between omega-3 and multiple myeloma risk
    Jian Li, Youxuan Li, Jun Wang, Yilang Zhou, Zhenzhen Wu, Yu Song, Guoqing Zhu, Jie Tian · 2025 · Scientific Reports
57. Identification of treatment effect modifiers and prognostic factors in newly diagnosed and relapsed or refractory multiple myeloma
    Jianming He, Karen Chiang, Xiwu Lin, Winghan Jacqueline Kwong, John T. Maringwa, Lingfeng Yang, Sandhya C. Nair, Mahmoud Hashim, Mi Jun Keng, Imtiaz A. Samjoo · 2025 · Journal of Comparative Effectiveness Research
58. Clinical analysis of hospital-acquired infections in patients with multiple myeloma: a study of 200 cases
    Hece Cai · 2025 · American Journal of Translational Research
59. Real-world outcomes of multiple myeloma in a resource-constrained setting: a 14-year experience from a tertiary cancer center in Jordan
    Abeer Yaseen, Mohammad Ma’koseh, Albatol Alamoush et al. · 2025 · Blood Global Hematology
60. The role of angiotensinogen, angiotensin II receptor type I and type II receptor polymorphisms (AGTR2 rs11091046, AGT rs699, AGTR1 rs5186, and AGT rs4762) in multiple myeloma
    İstemi Serin, Yasemin Oyacı, Sacide Pehlıvan, Elif Ertas, Fatıma Ceren Tunçel, Mustafa Pehlıvan · 2025 · Discover Oncology
61. Determining the factors affecting bortezomib’s adverse events in the treatment of newly diagnosed multiple myeloma
    Mengmeng Dong, Xiaoyan Han, Jingsong He, Yang Li, Gaofeng Zheng, Zhen Cai · 2025 · Hematology
62. From Physician-Driven to Patient-Centered: Transforming Multiple Myeloma Care Decisions
    Richa Thakur, Samer Al Hadidi · 2025 · JCO Oncology Practice
63. Serum heat shock protein family A member 9 protein as a biomarker for bortezomib resistance and poor prognosis in patients with multiple myeloma
    Lin Chen, Shuang Gao, Lin Li · 2025 · Anti-Cancer Drugs
64. An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies
    Danilo De Novellis, Salvatore Palmieri, Stefano Rocco, Daniele Derudas, Roberta Della Pepa, Daniela Roccotelli, Daniela Esposito, Chiara Masucci, Emilia Gigliotta, Maria Lucia Barone et al. · 2025 · Annals of Hematology
65. Hybrid Molecules of p53 Activators and Protoflavones to Target Multiple Myeloma
    Francisca Lopes, Gábor Girst, Rafael Rincón, Ricardo J. F. Ferreira, Lídia Gonçalves, Lucı́lia Saraiva, Hui‐Chun Wang, Muriel Cuendet, Attila Hunyadi, Maria M. M. Santos · 2025 · ChemMedChem
66. c-MAF protein expression in multiple myeloma
    M. V. Solov’eva, M. V. Solov’ev, M. V. Melnikova, A. M. Kovrigina, T. N. Obukhova, L. P. Mendeleeva · 2025 · Oncohematology
67. Whole genome CRISPR knockout screen reveals ID3 as a key regulator of myeloma cell survival via TCF3 and c-MYC
    Clara Andersson-Rusch, Md. Abu Hanif, Ingrid Quist-Løkken, Pål Sætrom, Miłosz Roliński, Johanna Fredrikke Nordstrand Moen, Naiara Campos Roman, Kristine Misund, Vidar Beisvåg, Per A. Aas et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
68. Adherence to treatment in patients with multiple myeloma and pain syndrome
    Д.Э. Выборных, Elmira Zalimkhanovna Irugova, Liubov V. Esina · 2025 · Oncohematology
69. Clinical Practice of Treatment Switch in Transplant-eligible Patients with Multiple Myeloma: An Exploratory Retrospective Analysis
    Sho Ikeda, Takahiro Kobayashi, Akihiro Kitadate et al. · 2025 · Internal Medicine
70. Singapore Myeloma Study Group consensus guidelines for the management of patients with newly diagnosed multiple myeloma
    Sanjay De Mel, Allison Ching Yee Tso, Cinnie Yentia Soekojo, Melissa Gaik Ming Ooi, Chi Ching Lim, Constance Teo, Yun Xin Chen, Melinda Si Yun Tan, Aditi Manjeri, Zhao Yuan Lee et al. · 2025 · Annals of the Academy of Medicine Singapore
71. Percorso di laboratorio raccomandato nella diagnosi, prognosi e follow-up delle gammopatie monoclonali: revisione 2025
    Maria Barrale, Mauro SASSO, Luigi Cinquanta, Maria Concetta Sorrentino, Rosalia PETRANCOSTA, Giuseppa SCEUSA, Maria T. TREVISAN, Salvatore Mangraviti, Bruno Biasioli, Ignazio Brusca · 2025 · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine
72. CD20 expression in plasma cell neoplasm and B-cell non-Hodgkin lymphoma with plasmacytic differentiation: insights into aberrant markers
    Narongdej Poonsombudloet, Sanya Sukpanichnant, Preeyawat Ngamdamrongkiat · 2025 · Journal of Hematology and Transfusion Medicine (วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต)
73. Clinical characteristics and prognosis of central nervous system involvement in multiple myeloma: a multicenter retrospective analysis from China
    Wenjing Li, Wei-Wei Tian, Jie Ma, Linyu Li, Zhihua Li, Jie Liu, Guorong Gao, Zhenfang Xi, Lan Zhang, Weihua Zhang et al. · 2025 · Research Square
74. Multiples Myelom: CAR-T-Zell-Therapie beim multiplen Myelom - Aktueller Stand, Herausforderungen und zukünftige Perspektiven
    Tim Richardson, Udo Holtick, Christof Scheid · 2025 · Trillium Krebsmedizin
75. Defining IgM Multiple Myeloma
    Mahin Bhatt, Anaëlle Zimmowitch, Hadiyah Y. Audil · 2025 · American Journal of Hematology
76. Ruxolitinib acts as a selective inhibitor of CaMKII-γ to impede the progression of Bortezomib-resistant multiple myeloma through AMPK-ULK1 axis-mediated autophagy pathway
    Mingdi Wang, Ruqi Liang, Zhihong Liu · 2025 · Research Square
77. A feasibility study of [18F] FDG PET/CT radiomics in predicting high-risk cytogenetic abnormalities in multiple myeloma
    Hong Chen, Jingxin Han, Haozhe Huang, Qi He, Xinqi Ren, Yu Fan, Chunkang Chang, Xuehai Ding, Quanyong Luo · 2025 · EJNMMI Research
78. Muscle Fat Infiltration in Patients with Multiple Myeloma: A Case–Control Study
    Tianshu Zhu, Hao Zhou, Dingzhe Zhang, Xiao Chen, Xuzhang Lu · 2025 · International Journal of General Medicine
79. Direct-to-patient research: Opportunity brings challenges
    Anne Quinn-Young, Michael Andreini, Arianna Haynes · 2025 · Cancer Treatment and Research Communications
80. NetFlow: A Framework to Explore Topological Representations of High-Dimensional Biomedical Data
    Rena Elkin, Jung Hun Oh, Anish K. Simhal, Joseph O. Deasy · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
81. Qualitative and Quantitative Inter-Observer Agreement of Multiparametric Whole-Body MRI in Staging and Follow-Up of Myeloma Patients
    Alice Rossi, Arrigo Cattabriga, Andrea Prochowski Iamurri · 2025 · Diagnostics
82. Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy
    S. Ito, Takashi Hamada, Masaru Nakagawa et al. · 2025 · Hematology Reports
83. RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma
    Yihua Wang, Qi Jia, Hongxiu Liu, Zhihua Li, Yanping Ma · 2025 · World Journal of Surgical Oncology
84. Lactylation-related multigene signature in multiple myeloma: integrated prognostic stratification, immune landscape profiling, and therapeutic guidance
    Wuyang Zhang, Shuai Ming, Peng Cheng et al. · 2025 · Immunologic Research
85. Return to employment outcomes in patients with multiple myeloma
    Nicoletta Libera Lilli, Manon Pequin, Léana Dulondel et al. · 2025 · British Journal of Haematology
86. Proteasome Inhibitor-Associated PRES in Multiple Myeloma: Pharmacovigilance Evidence of Risk Signals and Concomitant Drug Interactions
    Peipei Gao, Huajun Sun, Hongyan Wei · 2025 · Research Square
87. Determinants of Eligibility and Timing of Autologous Transplantation in Multiple Myeloma: The Role of R-MCI and Diagnostic Plasma Cell Burden
    Ozlem Candan, Arda Bayar, Narmin Naghizada · 2025 · Diagnostics
88. AI-derived five-gene signature predicts risk in multiple myeloma under bortezomib-based therapy
    Grazia Gargano, Susanna Anita Pappagallo, Angela Maria Quinto et al. · 2025 · Scientific Reports
89. A Multicenter, Feasibility Study Exploring Self-Administration of Chemotherapy in the Home Environment: The EASE Study
    Darius A. Ramrattan, Carole R. Chambers, Peter Raymond Duggan · 2025 · Annals of Pharmacotherapy
90. Successes and Challenges of Bispecific T-cell Engager Antibodies in the Treatment of Multiple Myeloma
    Ichiro Hanamura, Sivasundaram Karnan, Akinobu Ota, Akiyoshi Takami · 2025 · Internal Medicine
91. Biological Differences, Yet Comparable Outcomes: A Retrospective Study on the Impact of Treatment Strategy on Light Chain vs. Intact Immunoglobulin Myeloma
    G S Reshmy, S. Gayathri, Arundhathy Soman · 2025 · Indian Journal of Hematology and Blood Transfusion
92. Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing
    Baijun Fang, Zunmin Zhu, Yinyin Chang, Xiangxiang He, Shiyong Li, Manqian Li, Susu Yan, Dandan Zhu, Zhenling Li, Mao Mao · 2025 · Blood Advances
93. Intestinal Lymphangiectasia as a Rare Myeloma-Defining Event
    Lateefa Rashed Daraj, Shruti Prem Sudha, Mahera Roohi · 2025 · Cureus
94. Targeting GPRC5D With CAR‐T Cells in Relapse/Refractory Multiple Myeloma: Case Report and Literature Review
    Sijia Yan, Xi Ming, Jiaying Wu, Dan Peng, Mi Zhou, Yi Xiao · 2025 · Case Reports in Hematology
95. Mediastinal Extramedullary Plasmacytoma in the Absence of Classical Myeloma Markers: A Case Report
    Gonçalo Torres, Ana Patrícia Brito, Hermínia Teixeira, Jorge Cotter, Paula Mota · 2025 · Cureus
96. Expression and Clinical Significance of BCL2 Interacting Protein 3 Like (BNIP3L) in Serum of Patients with MM
    Yanyu Nong, Zengyi Xiong, Qicai Wang et al. · 2025 · Blood and Lymphatic Cancer Targets and Therapy
97. Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups
    Ghassan Zammar, Bradley Augustson, Elizabeth Moore et al. · 2025 · Clinical Lymphoma Myeloma & Leukemia
98. Genomic Alterations in Multiple Myeloma: A Comprehensive Landscape
    Smeeta Gajendra, Lata Rani, Gurvinder Kaur · 2025 · Indian Journal of Hematology and Blood Transfusion
99. THE EFFECT OF S-ADENOSYLMETHIONINE ON LIPID PROFILE PARAMETERS IN PATIENTS WITH MULTIPLE MYELOMA AND CONCOMITANT METABOLIC DYSFUNCTION–ASSOCIATED STEATOTIC LIVER DISEASE DURING CHEMOTHERAPY
    Y.O. Stadnik, G.S. Maslova · 2025 · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії
100. AdipoRon Suppresses Multiple Myeloma Proliferation Through AMPK ‐Mediated Metabolic Reprogramming and Apoptosis Induction
     Zhaohui Wang, Xiaotian Su, Ruru Guo, Yanqiu Han, Jing Zhang · 2026 · IUBMB Life